Myelodysplastic syndrome (MDS) is a collection of rare bone marrow and blood cell cancers that affects 4 in 100,000 people in the US. MDS causes fatigue, shortness of breath, and there’s an increased risk of bleeding complications and infection, with a reduction in quality of life. For patients living with MDS, treatment decisions can significantly impact quality of life, symptom management, and long-term outcomes. This presentation focuses on two different drug therapies that can be used in the management of MDS: Luspatercept and Lenalidomide.

Luspatercept is a supportive treatment that stimulates the development of red blood cells. This therapy can reduce the need for frequent blood transfusions and improve common symptoms such as fatigue and weakness. It is not curative but plays a key role in helping patients to feel better and maintain daily activities. In contrast, Lenalidomide is a targeted treatment used in certain subtypes of MDS. It works by directly interfering with cancer cell growth and helping the immune system recognize and attack abnormal cells.

The purpose of this research was to explore whether a supportive, symptom-relieving treatment like Luspatercept or a more aggressive, tumor-targeting treatment like Lenalidomide offers greater benefit to MDS patients. While both medications are effective, the choice often depends on the individual’s disease characteristics, goals of care, and tolerance to side effects.

From a nursing perspective, it is important to understand the mechanisms of action, side effect profiles, and implications of each drug. Nurses are responsible for educating patients about their treatment options, monitoring for adverse effects, and supporting patients through both physical and emotional aspects of care. As student nurses, learning about the differences between supportive and targeted therapies helps prepare us to advocate for individualized, evidence-based care.

This abstract highlights the importance of tailored treatment in MDS and the critical role nurses play in helping patients navigate complex therapy decisions. Ongoing research and nursing involvement are essential to improving outcomes for this vulnerable population.

Which medication therapy reduces the likelihood of bone marrow transplants. Bone marrow transplant is an option for patients because it can be a potential cure for MDS, however is the last resort because it comes with a lot of complications and can be very expensive. Which therapy was effective, had a better quality of life, and had fewer long-term complications for the MDS patient.